ATXS
Price
$3.88
Change
-$0.49 (-11.21%)
Updated
May 13, 04:59 PM (EDT)
Capitalization
238.72M
90 days until earnings call
BNTC
Price
$13.10
Change
-$0.04 (-0.30%)
Updated
May 13, 04:59 PM (EDT)
Capitalization
335.68M
Ad is loading...

ATXS vs BNTC

Header iconATXS vs BNTC Comparison
Open Charts ATXS vs BNTCBanner chart's image
Astria Therapeutics
Price$3.88
Change-$0.49 (-11.21%)
Volume$9.16K
Capitalization238.72M
Benitec Biopharma
Price$13.10
Change-$0.04 (-0.30%)
Volume$1.18K
Capitalization335.68M
ATXS vs BNTC Comparison Chart
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BNTC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. BNTC commentary
May 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Hold and BNTC is a Hold.

Ad is loading...
COMPARISON
Comparison
May 13, 2025
Stock price -- (ATXS: $4.37 vs. BNTC: $13.14)
Brand notoriety: ATXS and BNTC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 200% vs. BNTC: 70%
Market capitalization -- ATXS: $238.72M vs. BNTC: $335.68M
ATXS [@Biotechnology] is valued at $238.72M. BNTC’s [@Biotechnology] market capitalization is $335.68M. The market cap for tickers in the [@Biotechnology] industry ranges from $296.96B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileBNTC’s FA Score has 0 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • BNTC’s FA Score: 0 green, 5 red.
According to our system of comparison, BNTC is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 3 TA indicator(s) are bullish while BNTC’s TA Score has 4 bullish TA indicator(s).

  • ATXS’s TA Score: 3 bullish, 5 bearish.
  • BNTC’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both ATXS and BNTC are a bad buy in the short-term.

Price Growth

ATXS (@Biotechnology) experienced а -14.48% price change this week, while BNTC (@Biotechnology) price change was -8.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.66%. For the same industry, the average monthly price growth was +11.08%, and the average quarterly price growth was -7.46%.

Reported Earning Dates

ATXS is expected to report earnings on Aug 11, 2025.

BNTC is expected to report earnings on Sep 27, 2023.

Industries' Descriptions

@Biotechnology (+1.66% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BNTC($336M) has a higher market cap than ATXS($239M). BNTC YTD gains are higher at: 4.038 vs. ATXS (-51.119). BNTC has higher annual earnings (EBITDA): -23.8M vs. ATXS (-111.56M). ATXS has more cash in the bank: 328M vs. BNTC (78.3M). BNTC has less debt than ATXS: BNTC (137K) vs ATXS (5.35M). ATXS (0) and BNTC (0) have equivalent revenues.
ATXSBNTCATXS / BNTC
Capitalization239M336M71%
EBITDA-111.56M-23.8M469%
Gain YTD-51.1194.038-1,266%
P/E RatioN/AN/A-
Revenue00-
Total Cash328M78.3M419%
Total Debt5.35M137K3,907%
FUNDAMENTALS RATINGS
ATXS vs BNTC: Fundamental Ratings
ATXS
BNTC
OUTLOOK RATING
1..100
2361
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
90
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9494
PRICE GROWTH RATING
1..100
6538
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATXS's Valuation (61) in the Biotechnology industry is in the same range as BNTC (90). This means that ATXS’s stock grew similarly to BNTC’s over the last 12 months.

ATXS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BNTC (100). This means that ATXS’s stock grew similarly to BNTC’s over the last 12 months.

ATXS's SMR Rating (94) in the Biotechnology industry is in the same range as BNTC (94). This means that ATXS’s stock grew similarly to BNTC’s over the last 12 months.

BNTC's Price Growth Rating (38) in the Biotechnology industry is in the same range as ATXS (65). This means that BNTC’s stock grew similarly to ATXS’s over the last 12 months.

BNTC's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ATXS (100). This means that BNTC’s stock grew similarly to ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSBNTC
RSI
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 14 days ago
80%
Bullish Trend 12 days ago
86%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BNTC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VIKSX10.84N/A
N/A
Virtus KAR Small-Mid Cap Growth I
CLWFX71.04N/A
N/A
Columbia Large Cap Growth Inst2
FQITX13.52N/A
N/A
Fidelity SAI International Qly Idx
NWAUX14.46N/A
N/A
Nationwide GQG US Quality Eq A
AILLX24.48N/A
N/A
Aristotle Core Equity I-2

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with KYMR. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+3.31%
KYMR - ATXS
54%
Loosely correlated
+6.98%
TRDA - ATXS
53%
Loosely correlated
+5.25%
APGE - ATXS
51%
Loosely correlated
+6.14%
XENE - ATXS
50%
Loosely correlated
+2.37%
CRNX - ATXS
50%
Loosely correlated
+8.60%
More

BNTC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BNTC has been loosely correlated with TNGX. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if BNTC jumps, then TNGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BNTC
1D Price
Change %
BNTC100%
-3.60%
TNGX - BNTC
36%
Loosely correlated
+14.91%
MLTX - BNTC
30%
Poorly correlated
+4.45%
ATXS - BNTC
29%
Poorly correlated
+3.31%
ELDN - BNTC
28%
Poorly correlated
-0.69%
VRNA - BNTC
27%
Poorly correlated
+6.65%
More